바이러스 벡터 바이오 분석 시험 서비스 시장 규모, 점유율, 동향 분석 보고서 : 시험별, 바이러스 벡터별, 개발 단계별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Viral Vector Bioanalytical Testing Services Market Summary

The global viral vector bioanalytical testing services market size was estimated at USD 578.5 million in 2025 and is projected to reach USD 1,155.7 million by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The market growth is attributed to an increasing number of gene and cell therapy pipelines, rising regulatory focus on safety and potency validation, growing demand for AAV and lentiviral vectors, increasing clinical trial activity, and the expansion of biologics and advanced therapeutics, which are increasing testing volumes and outsourcing, in turn, boosting the demand for viral vector bioanalytical testing services.

The increasing number of clinical pipelines for cell and gene therapies, the rise in stringency in terms of regulatory requirements for characterization of viral vectors, increased use of AAV and lentivirus vectors in gene and cell therapies respectively, growing use of outsourcing by companies for their clinical and preclinical studies, advances in analytical techniques such as digital PCR and NGS, and complexities associated with the development of more complex and sensitive potencies and safety assays contribute towards increased demand for viral vector bioanalysis testing services. Furthermore, with the expansion of clinical pipelines, the need for more repetitive testing and a high volume of testing during clinical phases has increased revenue contribution from clinical phase testing processes.

In addition, regulatory authorities impose stringent requirements for safety, potency, and purity testing, which would result in increased expenditure for companies developing gene and cell therapies, with a focus on outsourcing testing services through long-term contracts. The aforesaid factors are expected to drive market growth over the forecast period. Additionally, innovations like digital PCR and next-generation sequencing (NGS) help boost sensitivity and efficiency, thus allowing detection of impurities even in very small concentrations while providing better compliance. Thus, the shift from regular assays to valuable testing services is likely to increase the demand for bioanalytical services. Also, outsourcing activities amongst small and medium biotech organizations creates greater reliance on CROs owing to limited capacity within these companies, thus making these companies outsource more frequently.

Nevertheless, the higher prices of bioanalytical testing, along with the lack of uniformity across assays, hinder the use of such technologies by startup companies, and differences in regulatory requirements across regions complicate operations for service providers. Thus, these factors are collectively impacting the market growth of the viral vector bioanalytical testing services industry.

Global Viral Vector Bioanalytical Testing Services Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global viral vector bioanalytical testing services market based on test, viral vector, development stage, end-use, and region:

• Test Outlook (Revenue, USD Million, 2021 - 2033)
• Titer & Quantification Testing
• Safety Testing
• Purity & Impurity Analysis
• Potency Assays
• Other Tests
• Viral Vector Outlook (Revenue, USD Million, 2021 - 2033)
• AAV (Adeno-Associated Virus)
• Lentiviral Vectors
• Other Viral Vectors
• Development Stage Outlook (Revenue, USD Million, 2021 - 2033)
• Preclinical
• Clinical
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical Companies
• Outsourced Service Providers (CROs, CMOs, CDMOs)
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test
  • 1.2.2. Viral Vector
  • 1.2.3. Development Stage
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Viral Vector Bioanalytical Testing Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Expanding Clinical Pipeline of Cell and Gene Therapies Using Viral Vectors
    • 3.2.1.2. Stringent Regulatory Requirements for Viral Vector Characterization
    • 3.2.1.3. Increasing Adoption of AAV And Lentiviral Vectors in Advanced Therapies
    • 3.2.1.4. Rising Outsourcing by Small and Mid-Sized Biopharmaceutical Companies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost and Technical Complexity of Advanced Bioanalytical Assays
    • 3.2.2.2. Lack Of Assay Standardization and Variability in Regulatory Expectations
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Viral Vector Bioanalytical Testing Services Market: Test Estimates & Trend Analysis

• 4.1. Viral Vector Bioanalytical Testing Services Market, By Test: Segment Dashboard
• 4.2. Viral Vector Bioanalytical Testing Services Market, By Test: Movement Analysis
• 4.3. Viral Vector Bioanalytical Testing Services Market Estimates & Forecasts, By Test, 2021 - 2033 (USD Million)
• 4.4. Titer & Quantification Testing
  • 4.4.1. Titer & Quantification Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Safety Testing
  • 4.5.1. Safety Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Purity & Impurity Analysis
  • 4.6.1. Purity & Impurity Analysis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Potency Assays
  • 4.7.1. Potency Assays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Other Tests
  • 4.8.1. Other Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Viral Vector Bioanalytical Testing Services Market: Viral Vector Estimates & Trend Analysis

• 5.1. Viral Vector Bioanalytical Testing Services Market, By Viral Vector: Segment Dashboard
• 5.2. Viral Vector Bioanalytical Testing Services Market, By Viral Vector: Movement Analysis
• 5.3. Viral Vector Bioanalytical Testing Services Market Estimates & Forecasts, By Viral Vector, 2021 - 2033 (USD Million)
• 5.4. AAV (Adeno-Associated Virus)
  • 5.4.1. AAV (Adeno-Associated Virus) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Lentiviral Vectors
  • 5.5.1. Lentiviral Vectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Other Viral Vectors
  • 5.6.1. Other Viral Vectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Viral Vector Bioanalytical Testing Services Market: Development Stage Estimates & Trend Analysis

• 6.1. Viral Vector Bioanalytical Testing Services Market, By Development Stage: Segment Dashboard
• 6.2. Viral Vector Bioanalytical Testing Services Market, By Development Stage: Movement Analysis
• 6.3. Viral Vector Bioanalytical Testing Services Market Estimates & Forecasts, By Development Stage, 2021 - 2033 (USD Million)
• 6.4. Preclinical
  • 6.4.1. Preclinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Clinical
  • 6.5.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Viral Vector Bioanalytical Testing Services Market: End Use Estimates & Trend Analysis

• 7.1. Viral Vector Bioanalytical Testing Services Market, By End Use: Segment Dashboard
• 7.2. Viral Vector Bioanalytical Testing Services Market, By End Use: Movement Analysis
• 7.3. Viral Vector Bioanalytical Testing Services Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 7.4. Biopharmaceutical Companies
  • 7.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Outsourced Service Providers (CROs, CMOs, CDMOs)
  • 7.5.1. Outsourced Service Providers (CROs, CMOs, CDMOs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Viral Vector Bioanalytical Testing Services Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. South Korea
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Australia
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Oman
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Qatar
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Charles River Laboratories
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Eurofins Scientific
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. WuXi AppTec
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Avance Biosciences Inc.
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. SGS SA
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Laboratory Corporation of America Holdings (LabCorp)
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Catalent, Inc.
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Lonza
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. KBI Biopharma
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Prolytix
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives